The Non-Malignant Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCAT 2024 | The need for a specialized multidisciplinary team when providing personalized pain treatment in SCD
Wally Smith, MD, Virginia Commonwealth University, Richmond, VA, highlights that implementing the biopsychosocial model of pain care for sickle cell disease (SCD) requires a multidisciplinary team approach similar to that used in cancer, diabetes, or hemophilia centers. Prof. Smith highlights his career-long efforts to establish these care teams for adults with SCD. This interview took place at the 19th Annual Scientific Conference of the Academy for Sickle Cell and Thalassaemia (ASCAT 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: Pfizer, Agios; DSMB: Novo Nordisk, Novartis.
